GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » 10-Year RORE %

Abattis Bioceuticals (Abattis Bioceuticals) 10-Year RORE % : 0.00% (As of Sep. 2019)


View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Abattis Bioceuticals's 10-Year RORE % for the quarter that ended in Sep. 2019 was 0.00%.

The industry rank for Abattis Bioceuticals's 10-Year RORE % or its related term are showing as below:

ATTBF's 10-Year RORE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.81
* Ranked among companies with meaningful 10-Year RORE % only.

Abattis Bioceuticals 10-Year RORE % Historical Data

The historical data trend for Abattis Bioceuticals's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals 10-Year RORE % Chart

Abattis Bioceuticals Annual Data
Trend Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abattis Bioceuticals Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Abattis Bioceuticals's 10-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Abattis Bioceuticals's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abattis Bioceuticals's 10-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Abattis Bioceuticals's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Abattis Bioceuticals's 10-Year RORE % falls into.



Abattis Bioceuticals 10-Year RORE % Calculation

Abattis Bioceuticals's 10-Year RORE % for the quarter that ended in Sep. 2019 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.007--0.194 )/( -0.898-0 )
=0.187/-0.898
=-20.82 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2019 and 10-year before.


Abattis Bioceuticals  (OTCPK:ATTBF) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Abattis Bioceuticals 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6
Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.

Abattis Bioceuticals (Abattis Bioceuticals) Headlines

From GuruFocus

Abattis Provides Marketing and Operational Updates

By Marketwired Marketwired 12-21-2018

Abattis Bioceuticals Announces Release of New Line of Vaporizers

By Marketwired Marketwired 05-22-2018

Abattis Provides Update on Conference Call

By Marketwired Marketwired 02-28-2019

Abattis Completes Sale of Northern Vine Interest

By Marketwired Marketwired 08-14-2018

Abattis Comments on BCSC Temporary Order

By Marketwired Marketwired 11-28-2018

Abattis Strengthens Management Team and Provides Company Updates

By Marketwired Marketwired 09-11-2018